HNGE · Hinge Health, Inc.

The thesis

Hinge Health sells digital musculoskeletal (MSK) care to employers and health plans, and it is growing above 50% a year while generating cash. Three brokers have since lifted targets to $130–$140, and the third-quarter report on 2 November 2026 decides whether revenue keeps pace with a price of $111.71.

The shares closed at $111.71 on 26 October 2026 on split- and dividend-adjusted daily closes, 0.3% below the 52-week high of $112.0 and up 50.8% over three months. The 14-day relative strength index (RSI), a momentum gauge, was 71.9. It stood at 80.3 on 13 October 2026, so the pace of the advance has cooled while the price has kept rising.

The narrative is maturing: the profitable-growth story has been public since the 4 August 2026 results, and the October gains came from target raises, KeyBanc on 16 October 2026, BofA Securities on 23 October 2026 and Stifel on 26 October 2026, not from new company figures. Those raises remove the earlier problem that the price had caught the average target, and they carry the rating from below to modestly above even odds against the S&P 500. The test is the $223–225 million revenue range management set on 4 August 2026; a figure below $223 million would break the case.

Bullish and bearish views on Hinge Health, Inc.

The bull case on Hinge Health, Inc. (HNGE), in brief: Growth already converts to cash. The bear case: The price already discounts a beat.

Bull case

• Growth already converts to cash. Second-quarter revenue was $212.8 million, up 53% year over year, with free cash flow of $99.6 million, per the company's 4 August 2026 results release. That quarter cleared the $200–202 million range management had raised to on 9 June 2026.
• Guidance has been raised twice this year. On 4 August 2026 the company lifted full-year 2026 revenue guidance to $856–860 million from $798–804 million. The company has beaten its own raised ranges, so the third-quarter range carries a track record.
• Analyst targets are moving up again. KeyBanc raised its target to $140 on 16 October 2026, BofA Securities to $130 from $110 on 23 October 2026, and Stifel to $130 from $115 on 26 October 2026. Needham ($115, 30 September 2026) and Truist ($112, 28 September 2026) also rate the shares Buy.
• Management is widening the product scope. Chief executive Daniel Perez told Bloomberg on 7 October 2026 that the company expects more acquisitions, particularly in hardware. The $105 million Cylinder Health gastrointestinal-care deal, announced 4 August 2026, completed on 1 September 2026 per the company.

Bear case

• The price already discounts a beat. The shares closed at $111.71 on 26 October 2026 after a 50.8% three-month gain, above the $105.13 consensus target one aggregator listed. Baird kept Neutral with a $90 target on 22 September 2026.
• Form 144 filings state intent to sell, and the sales appear on Form 4.
• Insiders sold into the run. MarketBeat's summary of Form 4 filings shows executive chairman Gabriel Mecklenburg sold 150,000 shares at a $93.22 average on 14 September 2026 and CFO James Budge sold 55,561 shares at $89.45 on 10 September 2026.
• Acquisitions add execution risk. The 7 October 2026 Bloomberg interview signals more deals in hardware, a business with different margins from software-led care. Cylinder Health has not yet appeared in a reported quarter.

Price setup

The 26 October 2026 close of $111.71 sits 0.3% under the 52-week high of $112.0. The 13 October 2026 close of $105.14 was the prior closing high, and the shares have held above it for two weeks. Before that, the 30 September 2026 close of $97.24 and an earlier $95.21 closing high marked the late-September advance.

MarketBeat put the 50-day moving average at $87.58 and the 200-day at $68.33 on 30 September 2026. Both were rising then, and the price has risen further since. The RSI of 71.9 on 26 October 2026 is below the 80.3 reading of 13 October 2026 but still above the conventional 70 line.

Crowding evidence is the imminent earnings date, the run of target raises within eleven days, and sponsor selling through Form 144 notices. Three of the latest targets sit 16% to 25% above the last close, so a revenue result near the low end of the range would leave the shares exposed to a gap lower.

Catalysts, next 30 days

• 2 November 2026: third-quarter 2026 results, after the US market close, with a call at 4:30 p.m. Eastern. It grades the $223–225 million revenue range and the $856–860 million full-year range, and it is the first quarter including Cylinder Health.
• ~2 November 2026, est.: fourth-quarter and 2027 commentary on the call. It shows whether employer selling-season demand turns into guided revenue.
• Through November: Form 4 filings from Insight Venture Partners and executives under 10b5-1 plans. They show whether the planned sales were completed.

What would change the view

Third-quarter revenue below $223 million, or a cut to the $856–860 million full-year range on 2 November 2026, would break the case, because the price rests on management continuing to beat its own raised ranges. A new hardware acquisition paired with a lower non-GAAP operating margin guide would weaken the cash-conversion argument.

On price, a weekly close below $105.14, under the 13 October 2026 closing high, would show the October advance has failed. A report above $225 million that still leaves the shares lower the next session would show the beat was already in the price. Further Insight Venture Partners Form 4 sales alongside a weaker close would point to supply outweighing analyst demand.

What it trades with

Hinge Health trades on its own results and on analyst target changes more than on index moves. Its closest public comparisons are other digital-health and employer-benefit platforms, which react to the same employer-spending and health-plan contracting news. No peer figures are cited here, so the note draws no sector conclusion.